# Breathlessness and cough during anticancer drug treatment: what is excluded first and how the symptom is eased

Source: https://onco.cc/protocols/breathlessness-and-cough-during-anticancer-treatment/  
OnCo record `breathlessness-and-cough-during-anticancer-treatment` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A new or worse cough or breathlessness during cancer drug treatment should be reported straight away. Your team first looks for a cause that can be treated, such as infection, a clot, fluid, anaemia or lung inflammation from the drug. Some drugs have their own rules for pausing or stopping. A hand-held fan, breathing techniques and sometimes low-dose morphine can ease breathlessness that remains.

## Summary

Scope. This page joins three kinds of source that answer different questions. The product labels say what to do about a breathing symptom on a named drug. The ESMO 2020 guideline covers breathlessness in patients with cancer in general, and the ASCO 2021 guideline covers dyspnoea in adults with advanced cancer; neither is written for a side effect of a particular drug. The CHEST 2017 guideline covers cough in adults with lung cancer that persists despite cancer treatment. Local protocols come first.

Cause first. ESMO: clinicians should identify and treat any potentially reversible condition contributing to breathlessness (II, A*); its table lists anaemia, asthma or COPD, heart failure, pleural and pericardial effusion, pneumonia, pulmonary embolism, superior vena cava syndrome, and pulmonary toxicity from chemotherapy or immunotherapy (withhold treatment and consider corticosteroids).

Product rules read. Atezolizumab and durvalumab (US labels): in suspected immune-mediated reactions, start a workup to exclude alternative causes, including infection; pneumonitis is then managed by grade (see the pneumonitis protocol). Sotorasib (US label and EU SmPC): immediately withhold for suspected ILD or pneumonitis and permanently discontinue if no other cause is identified. Adagrasib (US label): withhold, without the word immediately; the EU SmPC has no ILD warning and lists pneumonitis as a common adverse reaction. Zenocutuzumab (US label): immediately withhold, corticosteroids as clinically indicated, permanently discontinue for confirmed grade 2 or higher. Belzutifan: monitor oxygen saturation before and periodically during treatment; the US label acts on a pulse oximeter reading below 88% with exercise (consider withholding) or at rest (withhold), the EU SmPC on CTCAE grade, with grade 3 defined by the same resting reading (grade 3 without symptoms: consider supplemental oxygen and continuing or withholding). Dasatinib: the EU SmPC asks that dyspnoea and fatigue be evaluated for pleural effusion, pulmonary oedema, anaemia or lung infiltration, with the dose reduced or interrupted meanwhile, and that pulmonary arterial hypertension be considered if nothing is found; the US label asks for a prompt chest x-ray or other imaging for symptoms of pleural effusion such as new or worsened dyspnoea or dry cough; both labels stop dasatinib permanently if it is confirmed. Carfilzomib (both): evaluate dyspnoea to exclude cardiac failure and pulmonary syndromes, and stop for grade 3 or 4 until resolved. Pazopanib: the EU SmPC asks for close observation for pneumothorax; the US label reports it in 3.3% of people in the sarcoma trial and gives no instruction beyond counselling.

Symptom. ESMO: consider a hand-held fan (II, B), teach breathing techniques, pacing and positions (II, B), palliative oxygen is not recommended at a resting SpO2 of 90% or more (II, D), regular low-dose oral morphine is the first-line drug for severe chronic breathlessness that persists despite non-drug measures (II, B), and benzodiazepines should not be first-line (III, D). The ASCO abstract agrees on the order and says systemic opioids should be offered when non-drug measures give inadequate relief. CHEST, for cough in lung cancer: assess for co-existing causes, then cough suppression exercises, a demulcent linctus, then an opioid derivative (Grade 2C).

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: dyspnoea on cancer treatment; shortness of breath on anticancer drugs; cough on immunotherapy; cough on sotorasib; belzutifan hypoxia; low oxygen on Welireg; dasatinib pulmonary arterial hypertension; carfilzomib dyspnoea; pazopanib pneumothorax; treatment-emergent dyspnea
- Tags: protocol; symptom-management; acute-oncology

## Connected records

- protocols: [Acute oncology telephone triage: the 24-hour helpline and the UKONS red, amber and green grading](https://onco.cc/protocols/acute-oncology-telephone-triage/), [Anticoagulation for a blood clot in a person with cancer: choice of drug, duration and special situations](https://onco.cc/protocols/cancer-associated-vte-treatment/), [Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs](https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/), [Immune-related pneumonitis from checkpoint inhibitors, by grade](https://onco.cc/protocols/irae-pneumonitis/), [Indwelling pleural catheter: draining fluid from the chest at home](https://onco.cc/protocols/indwelling-pleural-catheter-drainage-at-home/), [Interstitial lung disease on antibody-drug conjugates and targeted drugs: monitoring and management by grade](https://onco.cc/protocols/interstitial-lung-disease-on-antibody-drug-conjugates-and-targeted-drugs/), [Malignant pericardial effusion: tamponade, drainage, cytology and preventing recurrence](https://onco.cc/protocols/malignant-pericardial-effusion/), [Strong opioids for cancer pain: starting, titrating, rescue doses and preventing constipation](https://onco.cc/protocols/strong-opioids-for-cancer-pain/)
- terms: [Anaemia](https://onco.cc/terms/anaemia/), [Interstitial lung disease (ILD) / pneumonitis](https://onco.cc/terms/ild/), [Malignant pleural effusion and ascites](https://onco.cc/terms/pleural-effusion/), [Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain](https://onco.cc/terms/lung-palliation-breathlessness-effusion-obstruction/), [Pneumonitis](https://onco.cc/terms/pneumonitis/), [Superior vena cava obstruction](https://onco.cc/terms/superior-vena-cava-obstruction/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Belzutifan](https://onco.cc/drugs/belzutifan/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Dasatinib](https://onco.cc/drugs/dasatinib/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Morphine](https://onco.cc/drugs/morphine/), [Pazopanib](https://onco.cc/drugs/pazopanib/), [Sotorasib](https://onco.cc/drugs/sotorasib/), [Zenocutuzumab](https://onco.cc/drugs/zenocutuzumab/)
- institutions: [American Society of Clinical Oncology (ASCO)](https://onco.cc/institutions/asco/), [European Medicines Agency](https://onco.cc/institutions/ema/), [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)

---
JSON: https://onco.cc/api/v1/entities/breathlessness-and-cough-during-anticancer-treatment.json